Global biopharmaceutical firm Harbour BioMed (HBM) announced on Thursday the completion of a Series B+ round of financing at $75 million to accelerate the advancement of its clinical-stage compounds and next-generation biotherapeutics for treating cancer and immunological diseases.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in
